High tierRandomized Controlled TrialCitation verified
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M Ridker, Brendan M Everett, Tom Thuren, Peter Libby, Robert J Glynn, CANTOS Trial Group - New England Journal of Medicine, 2017
A randomized, double-blind trial of canakinumab (an anti-interleukin-1-beta antibody) in patients with prior MI and elevated hs-CRP. The 150 mg dose significantly reduced recurrent cardiovascular events compared with placebo - without lowering LDL - providing direct evidence that inflammation is an independent, modifiable contributor to cardiovascular risk.
Key findings
- Canakinumab 150 mg every 3 months reduced recurrent cardiovascular events vs placebo, independent of any lipid lowering.
- Primary endpoint rates: 4.50 (placebo) vs 3.86 (150 mg) events per 100 person-years.
- First trial to show that reducing inflammation alone, with no lipid change, lowers cardiovascular events.
Effect measures
- Hazard Ratio: Significant reduction in MACE at the 150 mg dose vs placebo (event rates 3.86 vs 4.50 per 100 person-years)
Why this evidence tier (High)
- Risk of bias:
- Large randomized, double-blind, placebo-controlled trial - low risk of bias.
- Precision:
- n=10,061 with adjudicated events; adequately powered.
- Directness:
- Directly tests whether lowering inflammation (without lipid change) reduces hard cardiovascular events.
- Consistency:
- Coheres with observational residual-inflammatory-risk data.
- Funding / COI:
- Industry-sponsored (Novartis, per the wider record); a reason for caution though the design is rigorous.
High certainty that inflammation is an independent causal contributor; this supports the context-modifier claim without implying high LDL is benign.
- Population:
- 10,061 patients with previous myocardial infarction and hs-CRP >=2 mg/L; median follow-up 3.7 years.
- Conflicts of interest:
- Sponsored by the canakinumab manufacturer; lead investigators have related disclosures. See source.
- Funding:
- Industry-sponsored (Novartis; not captured on the fetched abstract).
Limitations
- Secondary prevention (prior MI) population; not a primary-prevention or metabolically-healthy cohort.
- Canakinumab is not in routine cardiovascular use (cost, infection risk); the trial is mechanistic proof, not a treatment recommendation.